Objectives: Pivmecillinam is a safe beta-lactam for use in pregnancy. It has been widely used for the treatment of lower urinary tract infections (UTIs) in the Nordic countries where its efficacy, minor impact on the microbiota, and low level of resistance among the Escherichia coli strains have been proven. However, susceptibility data related to E. coli involved in asymptomatic bacteriuria and lower UTIs in pregnant women is lacking. We aimed to support the 2015 recommendations issued by the French Infectious Diseases Society (SPILF) on gestational UTI, with a particular focus on pivmecillinam.
Material And Methods: Antimicrobial susceptibility testing was performed by 12 hospitals with a maternity department on 235 E. coli strains isolated from the urine of pregnant women. Susceptibility to mecillinam was tested by disk diffusion method using the 2015 recommendations of the antibiogram committee of the French microbiology society (CA-SFM).
Results: Global susceptibility to mecillinam was 86.4%. Susceptibility to mecillinam was 96.5% for strains susceptible to amoxicillin-clavulanic acid and 38.7% for resistant strains. All six extended-spectrum beta-lactamase-producing E. coli strains were susceptible to mecillinam.
Conclusion: Given the efficacy and safety of pivmecillinam during pregnancy, it may be used for the documented treatment of asymptomatic bacteriuria and acute cystitis in pregnant women. It also represents an alternative for the treatment of multidrug-resistant bacterial infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medmal.2016.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review.
Ann Pharmacother
December 2024
Department of Pharmacy Practice, ETSU Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA.
Article Synopsis
- - The review highlights the efficacy and safety of pivmecillinam in treating uncomplicated acute cystitis, based on data from six randomized controlled trials showing effectiveness at doses of 200 to 400 mg taken three times daily for 3 to 7 days.
- - Higher doses (400 mg) and longer treatment durations resulted in better clinical and bacteriologic outcomes, while pivmecillinam is particularly beneficial for populations not commonly approved by the FDA, like men or pregnant women.
- - As antibiotic resistance increases, pivmecillinam offers a new, potentially effective outpatient treatment option for uncomplicated acute cystitis in the U.S., with a focus on cost and its low resistance profile in managing uropathogens. *
Avian Pathogenic Isolated in Poultry Farms in Bangladesh that Use Antibiotics Extensively.
Microb Drug Resist
November 2024
Agribio, Agriculture Victoria Research, Bundoora, Australia.
Colibacillosis caused by avian pathogenic (APEC) is causing economic losses to the global poultry industry. Increased prevalence of antibiotic resistance in APEC is the leading cause for increased indiscriminate use of various antimicrobial compounds in farms. The study aimed to investigate the presence of phenotypic and genotypic markers for antibiotic resistance, metals, and biocides in APEC from Bangladeshi poultry and details about the antimicrobials used in poultry farms.
View Article and Find Full Text PDFActivity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics.
J Glob Antimicrob Resist
December 2024
Maxel Consulting ApS, Jyllinge, Denmark.
Article Synopsis
- A study was conducted to investigate the effectiveness of mecillinam and pivmecillinam against urinary tract infection (UTI) bacteria in the U.S. from 2017 to 2020, highlighting its potential as a treatment option.
- Mecillinam showed high susceptibility rates (94.9%) among UTI-causing Enterobacterales, especially against extended-spectrum beta-lactamase (ESBL)-positive strains (98.2%).
- The findings support the clinical development of mecillinam as a promising first-line therapy for uncomplicated UTIs, especially when other common antibiotics showed higher resistance rates.
Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.
J Antimicrob Chemother
October 2024
Laboratoire de Bactériologie-Hygiène, CHU de Toulouse, Université de Toulouse Paul Sabatier, Toulouse, France.
Objectives: Performance evaluation of routine laboratory methods to determine the susceptibility of Enterobacterales urinary isolates to fosfomycin (oral administration) and mecillinam.
Methods: We collected 347 Enterobacterales isolates from monomicrobial midstream urine samples from women with significant bacteriuria and leukocyturia. Mostly non-Escherichia coli isolates (i.
Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.
Open Forum Infect Dis
June 2024
Department of Clinical Microbiology, Central Hospital, Växjö, Sweden.
Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!